Tabrecta (Capmatinib) is a kinase inhibitor used for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET (Mesenchymal-Epithelial Transition) exon 14 skipping as detected by an FDA-approved test.
Dosage: The recommended dosage of Capmatinib is 400 mg orally twice daily with or without food. Swallow the Capmatinib tablets whole. Do not break, crush or chew the tablets. If a patient misses or vomits a dose, instruct the patient not to make up the dose, but to take the next dose at its scheduled time.
Side Effects: The most commonly reported capmatinib side effects (≥ 20%) include:
- peripheral edema
- decreased appetite
Warnings and Precautions:
- Monitor patients with capmatinib dose for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever).
- Monitor liver function tests (including ALT, AST, and total bilirubin) before initiating capmatinib fda label drug, every two weeks during the first 3 months of treatment, then once a month.
- Patients taking treatment with capmatinib should use precautionary measures against ultraviolet exposure such as use of sunscreen or protective clothing while on treatment.
- The capmatinib 200 mg tablet can cause fetal harm if administered to a pregnant woman. Females of reproductive age must inform their health specialist of a known or suspected pregnancy.
- Respective women should not breastfeed during treatment with capmatinib 150 mg and for one week after the last dose.